43.51 USD
-0.32 (-0.73%)
EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. EXEL scores excellent points on both the profitability and health parts. This is a solid base for a good stock. EXEL is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make EXEL a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
EXEL had positive earnings in the past year.
In the past year EXEL had a positive cash flow from operations.
EXEL had positive earnings in each of the past 5 years.
Each year in the past 5 years EXEL had a positive operating cash flow.
1.2 Ratios
EXEL has a Return On Assets of 24.01%. This is amongst the best in the industry. EXEL outperforms 97.55% of its industry peers.
The Return On Equity of EXEL (31.37%) is better than 97.74% of its industry peers.
With an excellent Return On Invested Capital value of 26.31%, EXEL belongs to the best of the industry, outperforming 98.87% of the companies in the same industry.
EXEL had an Average Return On Invested Capital over the past 3 years of 10.78%. This is significantly below the industry average of 18.28%.
The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(26.31%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROIC | 26.31% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
With an excellent Profit Margin value of 29.63%, EXEL belongs to the best of the industry, outperforming 95.66% of the companies in the same industry.
In the last couple of years the Profit Margin of EXEL has declined.
The Operating Margin of EXEL (35.85%) is better than 97.55% of its industry peers.
EXEL's Operating Margin has declined in the last couple of years.
EXEL's Gross Margin of 96.63% is amongst the best of the industry. EXEL outperforms 96.60% of its industry peers.
EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
The number of shares outstanding for EXEL has been reduced compared to 1 year ago.
EXEL has less shares outstanding than it did 5 years ago.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
EXEL has an Altman-Z score of 12.79. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
EXEL's Altman-Z score of 12.79 is amongst the best of the industry. EXEL outperforms 84.53% of its industry peers.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.79 |
ROIC/WACC2.98
WACC8.82%
2.3 Liquidity
EXEL has a Current Ratio of 3.75. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.75, EXEL is in line with its industry, outperforming 45.66% of the companies in the same industry.
EXEL has a Quick Ratio of 3.68. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL's Quick ratio of 3.68 is in line compared to the rest of the industry. EXEL outperforms 46.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 |
3. Growth
3.1 Past
EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
EXEL shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.65% yearly.
The Revenue has grown by 9.93% in the past year. This is quite good.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
3.2 Future
EXEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.76% yearly.
EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.99% yearly.
EPS Next Y44.91%
EPS Next 2Y30.69%
EPS Next 3Y29.97%
EPS Next 5Y25.76%
Revenue Next Year7.84%
Revenue Next 2Y9.9%
Revenue Next 3Y11.39%
Revenue Next 5Y9.99%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EXEL is valuated rather expensively with a Price/Earnings ratio of 18.36.
Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 94.91% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of EXEL to the average of the S&P500 Index (26.51), we can say EXEL is valued slightly cheaper.
The Price/Forward Earnings ratio is 13.77, which indicates a correct valuation of EXEL.
96.42% of the companies in the same industry are more expensive than EXEL, based on the Price/Forward Earnings ratio.
EXEL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.36 | ||
| Fwd PE | 13.77 |
4.2 Price Multiples
EXEL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.04% of the companies in the same industry.
96.79% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.96 | ||
| EV/EBITDA | 11.94 |
4.3 Compensation for Growth
EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 29.97% in the coming years.
PEG (NY)0.41
PEG (5Y)1.45
EPS Next 2Y30.69%
EPS Next 3Y29.97%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:EXEL (1/2/2026, 3:17:50 PM)
43.51
-0.32 (-0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.38%
Inst Owner Change-0.35%
Ins Owners2.17%
Ins Owner Change-2.56%
Market Cap11.67B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts76.3
Price Target46.18 (6.14%)
Short Float %8.71%
Short Ratio7.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)0.62%
PT rev (3m)2%
EPS NQ rev (1m)5.12%
EPS NQ rev (3m)22.93%
EPS NY rev (1m)11.84%
EPS NY rev (3m)10.88%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)0.27%
Revenue NY rev (1m)0.59%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.36 | ||
| Fwd PE | 13.77 | ||
| P/S | 5.1 | ||
| P/FCF | 14.96 | ||
| P/OCF | 14.75 | ||
| P/B | 5.4 | ||
| P/tB | 5.56 | ||
| EV/EBITDA | 11.94 |
EPS(TTM)2.37
EY5.45%
EPS(NY)3.16
Fwd EY7.26%
FCF(TTM)2.91
FCFY6.68%
OCF(TTM)2.95
OCFY6.78%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.41
PEG (5Y)1.45
Graham Number20.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROCE | 33.48% | ||
| ROIC | 26.31% | ||
| ROICexc | 44.11% | ||
| ROICexgc | 46.12% | ||
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% | ||
| FCFM | 34.08% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 37.81% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 93.06% | ||
| Profit Quality | 115.03% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 | ||
| Altman-Z | 12.79 |
F-Score8
WACC8.82%
ROIC/WACC2.98
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y44.91%
EPS Next 2Y30.69%
EPS Next 3Y29.97%
EPS Next 5Y25.76%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.84%
Revenue Next 2Y9.9%
Revenue Next 3Y11.39%
Revenue Next 5Y9.99%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year54.05%
EBIT Next 3Y25.06%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
Can you provide the valuation status for EXELIXIS INC?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
Can you provide the profitability details for EXELIXIS INC?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
Can you provide the financial health for EXEL stock?
The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.
What is the expected EPS growth for EXELIXIS INC (EXEL) stock?
The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 44.91% in the next year.